NCT05244213View on ClinicalTrials.gov

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 4, 2022

Primary Completion Date

June 5, 2024

Study Completion Date

December 1, 2025

Conditions
Non-small Cell Lung CancerEGFR Activating Mutation
Interventions
BIOLOGICAL

Sintilimab

200mg Q3W

DRUG

Carboplatin

AUC 5, d1 every 3 weeks

DRUG

Nab paclitaxel

260 mg/m2, d1 every 3 weeks

Trial Locations (1)

510080

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER